CARLSBAD, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company")
(TSXV:ASG) announces that it has granted options (the "Options") to acquire 462,500 common shares of the Company to certain
directors of the Company. The Options are exercisable at a price of CDN$0.20 per common share and vest one third on the first,
second and third annual anniversaries from the date of grant. The Options have a term of five years and are subject in all respects
to the terms of the Company's stock option plan.
The Option grants constitute a "related party transaction" within the meaning of Multilateral Instrument 61-101
- Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSX Venture
Exchange, but are otherwise exempt from the formal valuation and minority approval requirements of MI 61-101.
Neither the TSX Venture Exchange, nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange), accepts responsibility for the adequacy or accuracy of this release.
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a
series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to
position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies.
Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying
the Complex.
For additional information, or for a copy of the early warning report, please contact: Aurora Spine Corporation Trent Northcutt President and Chief Executive Officer (760) 424-2004 Eric Fronk Chief Financial Officer (760) 424-2004 www.aurora-spine.com
